The EBOVAC2 project is organising its first training session which will be dedicated to French-speaking African countries on the Methodology of vaccine clinical trials

Read more

 
   

Welcome to ebovac2

The EBOVAC2 project is one of 8 projects funded under IMI Ebola+ programme that was launched in response to the Ebola virus disease outbreak. The project aims to assess the safety and efficacy of a novel prime boost preventive vaccine regimen against Ebola Virus Disease (EVD).

To expedite the development of the vaccine regimen, Phase 2 trials and a Phase 2B study will be carried out in parallel and therefore coordinated by two separate teams within EBOVAC1 (Phase 1 and Phase 2B large scale safety and immunogenicity study) and EBOVAC2 (Phase 2 trial) projects.

lab                                           © Janssen


Between them, the EBOVAC projects will assess, through phase I and phase 2 trials in Europe and Africa, as well as a Phase 2B large scale safety and immunogenicity study, the safety and tolerability of the vaccine regimen in response to the urgent public health need raised by the Ebola epidemic.

Read more

News

  • 23 April 2019

    An Ebovac2 poster was selected among 13 out of approx. 2 500 posters on the top rated of the ECCMID 2019. To view the poster, please, click here. Congratulations to the authors!

  • 24 September 2018

    The 7th newsletter is available here. This issue announces Ebovac2 4th annual meeting in Nairobi (Kenya) in January 2019. 

  • 17 January 2018

    Clinical Trial Training - Bobo Dioulasso, BURKINA FASO, 23-26 January, 2018. For more information

  • 12 September 2017

    The 3rd EBOVAC1/2 Annual meeting will be held in Amsteram, the Netherlands 8-10 January 2018. Participants include consortium members and representatives of sites where the project clinical trials are being carried out.

  • 15 May 2017

    Based on final Phase 1 data published in JAMA: The Journal of the American Medical Association, the prime-boost Ebola vaccine regimen induced an antibody response that persisted in 100 percent of healthy volunteers to at least 1 year following vaccination. The results are from the EBOVAC1 study EBL1001 conducted by the Oxford Vaccine Group in the UK.

  • 15 May 2017

    Victoria Derbyshire reporter Catrin Nye went to visit the Oxford Vaccine Group looking for volunteers who participated in the EBL2001 study. Prof. Andrew Pollard (Professor of Paediatric Infection and Immunity and Oxford Vaccine Group PI for EBOVAC1 and EBOVAC2 ) and study volunteers were interviewed.Watch here : http://www.bbc.co.uk/news/uk-39202974

More news

  • Ebola: background

    What is Ebola?

  • Phase 2 trials

    Find out more about EBOVAC2 trials

  • Work programme

    EBOVAC2 is organised into 6 workpackages (WP)

  • Ebola+ programme

    Contributes to efforts to tackle a wide range of challenges in Ebola research

ebovac2 in numbers

ebovac2 in numbers

  • 6 ORGANISATIONS

    4 institutes, 1 Industrial partner,1 private company
    in charge of Management

  • 3 EUROPEAN UNION MEMBER

    states involved

  • BUDGET

    €22,790,820 (IMI JU funding);
    EFPIA contribution: €15.1 million

  • 3 YEAR-DURATION

    1st December 2014 – 30 November 2017

ebovac1 trials

  • Phase 1

    Trial countries: UK and selected African countries

  • Large-scale efficacy study or expanded safety and immunogenicity study in Sierra Leone

    More information on ebovac1 trials coming soon

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 115861.
This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA

Ebovac2 © 2015. By ML COM